IBI Blogs On Retirement Secrets: How You Can Capture This Bull Market?
Integrated biosci research, consultant
Seeking Alpha Analyst Since 2013
As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading.
Since inception, our flagship portfolio has delivered over 31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains.
Check out some of our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook.
In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis. The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.
Follow us for the latest research. And, take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!
Check out Dr. Harvey’s LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out Integrated BioSci Investing!
Right now, you're in the middle of a raging bull market.
Most stocks you pick will give you gains.
However, some companies perform far better than others.
To reap the most profits, you should focus on those companies.
In the figure below, you can see that the IBI stocks - TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), and CryoPort (CYRX) - correspondingly deliver 186.1%, 147.3%, and 122.0%, gains, for the past 6-months!
That's far better than the corresponding 34.5% gains for Starbucks (SBUX) and the REIT stock, American Tower Corp (AMT).
It's just like picking the best of the best.
Hence, you make the most money when you choose niche leaders before they grow in prominence.
Many IBI stocks procured multiple fold gains over the years because I only pick upcoming leaders.
Since my recommendation, TGTX delivers over 3 fold profits, CYRX nearly 8-folds gain, and CRSP also nearly 8-folds.
And that can make a difference between you getting a Rolls Royce Phantom vs. a Lexus.
As you can see, conventional wisdom tells you to go for the blue-chip equities.
And it urges you not to buy during a bear market.
The excuse is to bunker down on "high-quality equities."
When you take a closer inspection, a larger size doesn't mean higher quality.
The chances of a larger company like Starbucks to double is next to nothing.
After all, there is already a Starbucks around the corners of your neighborhood.
Therefore, it's not realistic to see Starbucks to double in size.
Conventional wisdom also told you that REITs yield the best returns.
That's not the case.
Look at AMT in the chart below. You see that it doesn't do so well in the past-6 months.
As I wrote before the Corona bear market crash back in March: all stocks tumbled in a bear market.
Here're what I wrote back in 2019,
The truth is ...
When the next recession hits, all your stocks, including dividends will suffer. You don't have to believe me. But think back to the 2008 Great Recession ...
Hence, I strongly believe that your goal right now is to bank as much profits as you could in high growth investments. That way, you can cushion the next market downturn.
Of note, it's important that you track performance over time. Else, you don't know facts from fiction.
Now in an upmarket like right now, growth biotech will grow much faster than blue-chip companies.
That's why you should stick to high-quality growth biotech.
And your sweet spot should be at $1B in market cap.
You may think I just pick a random number.
However, that's not the case.
My mentor (by book), Phillip Fisher, prefers a company in the $1B in sales to hold for the ultra-long-haul.
It takes tremendous capital to fund a drug from bench research to commercialization.
As such, a biotech company needs to raise capital through an offering.
If the market cap is too small, says a $100M, it'll dilute the value of your investment.
With $1B in market cap, a public offering won't cause your shares to crash.
That being said, your best bet in getting the most profits out of this mega bull market is to focus on growth biotech.
Make sure you choose Phillip Fisher's growth equities, which have the following characteristics:
First, companies having a good chance of delivering strong clinical data.
Second, firms having a lead drug with a robust market.
Third, bio-stocks powered by top-notch management.
Fourth, you harness the aggregate wisdom of an expert community.
Fifth, companies having a true worth greater than their current share price.
Sixth, companies with a strong balance sheet.
If you believe you deserve more for yourself, more from your life, and your stocks, check out IBI.
As you can see, I do a lot of stock research and recommendations inside IBI. And I help you become the newer and better you. Some of our big winners include TG Therapeutics (TGTX), CRISPR Therapeutics (CRSP), CryoPort (CYRX), Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM), Corium International (CORI), Kite Pharma(KITE), Juno Therapeutics (JUNO), Sparks Therapeutics (ONCE), Tesaro(TSRO), Mirati Therapeutics (MRTX), etc ...
At IBI: Everyone is getting smarter. Everyone is respected. You don't feel like a fool. And you’re a part of something bigger than yourself.
Inside IBI, we stay ahead of the market.
I'm so confident in the value of my service that I'm giving you a 2-week FREE trial, money-back guarantee.
GET YOUR FREE GIFT TO PROFITABILITY NOW!
Analyst's Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
As a medical doctor/market expert, I'm not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I'm also NOT responsible for the action of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.